The vaccine was found to be safe and well-tolerated when administered at the maximum tolerated dose. The results indicated that moving the program into Phase 2 development is feasible. A combination of Keytruda® and the vaccine was successful in generating T cell responses, with no significant additional side effects observed. This outcome boosts confidence in the plans for a Phase 2 neoadjuvant study.